Tolerability: Clinical Trials

26 trials for Tolerability, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

26 completed. 26 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 126Completed 26
Phase 21Completed 1

Follow Tolerability: new trials by email Literature Review of Tolerability trials Research Report on Tolerability

Trials (filtered) newest first · largest first

All 26 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase 1 Study of Y-3 in US Healthy Volunteers.
Y-3 for injection, Placebo - Safety, Tolerability
Phase 1CompletedNeurodawn Pharmaceutical Co., Ltd.202025-02-042025-12-18
SB17170 Phase1 Trial in Healthy Volunteer
SB17170, Placebo - Safety Issues, Tolerability
Phase 1CompletedSPARK Biopharma642023-05-242024-03-21
Phase 1 Clinical Trial of RHN-001 in Healthy Adult Volunteers
RHN-001 (one tablet 750mg), RHN-001 (750mg * 2 Tablets) - Safety, Tolerability
Phase 1CompletedRH Nanopharmaceuticals642023-03-092023-05-06
Pharmacokinetics, Safety, and Tolerability of Intramuscular 5-MeO-DMT in Healthy Volunteers
5-methoxy-N,N-dimethyltryptamine succinate salt, Placebo - Pharmacokinetics, Safety
Phase 1CompletedUsona Institute542022-12-272023-11-30
Effect of Clarithromycin on PK of Linaprazan, Linaprazan on PK of Clarithromycin and Linaprazan on PK of Midazolam
Linaprazan glurate, Drug drug interaction (DDI) - Clarithromycin (Part I), Drug drug interaction (DDI) - Midazolam (Part 2) - Safety Issues, Pharmacokinetics
Phase 1CompletedCinclus Pharma Holding AB352022-11-272025-01-03
Clinical Trial on Pharmacokinetics and Tolerability of AP707
AP707 - Pharmacokinetics, Tolerability
Phase 1CompletedCannaXan GmbH122022-03-022022-07-27
A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7503 in Healthy Participants
AZD7503, Placebo - Safety, Tolerability
Phase 1CompletedAstraZeneca562021-12-062025-02-19
Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors
IPG7236 - Safety Issues, Tolerability
Phase 1 / Phase 2CompletedNanjing Immunophage Biotech Co., Ltd342021-11-152026-07-08
Safety, Tolerability and Pharmacokinetics of AM1476 in Healthy Subjects
AM1476, Placebo - Safety, Tolerability
Phase 1CompletedAnaMar AB972020-12-162024-08-02
Clinical Study for the Evaluation of Safety and Tolerability of PRO-172 Ophthalmic Solution+
Bepotastine Besilate - Safety, Tolerability
Phase 1CompletedLaboratorios Sophia S.A de C.V.222020-09-242025-07-16
Clinical Trial on Pharmacokinetic and Tolerability of AP701
AP701 - Pharmacokinetic, Tolerability
Phase 1CompletedCannaXan GmbH152020-01-112021-03-10
Safety, Tolerability and Immune Effects of the Nasal Foralumab in Healthy Human Volunteers
Placebo, Foralumab Nasal - Safety, Tolerability
Phase 1CompletedTiziana Life Sciences LTD272018-11-122025-03-17
A Single Ascending Dose Study To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of AZD9567.
AZD9567 Monohydrat, Placebo oral suspension/ Placebo capsule, Prednisolone - Safety, Tolerability
Phase 1CompletedAstraZeneca722015-11-182018-10-04
A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 After Single Ascending Doses to Healthy Males
AZD9977, oral suspension, Placebo, oral suspension, AZD9977, oral solution - Safety, Tolerability
Phase 1CompletedAstraZeneca1962015-07-012017-04-28
Single Ascending Dose Study Using DS-1971 to Assess Safety, Tolerability, and Pharmacokinetics in Healthy Participants.
DS-1971, placebo - Safety, Tolerability
Phase 1CompletedDaiichi Sankyo642014-03-012018-12-24
Assessment of Single Doses of Oral Dexanabinol in Healthy Subjects
Dexanabinol Dose Level 1, Dexanabinol Dose Level 2, Dexanabinol Dose Level 3 - Safety, Tolerability
Phase 1Completede-Therapeutics PLC402014-01-012016-05-23
A Clinical Trial to Investigate Safety and Tolerability of ASP7962 in Healthy Humans
ASP7962, Placebo - Safety, Tolerability
Phase 1CompletedAstellas Pharma Europe B.V.482013-11-012014-07-11
A Dose Escalating Study to Determine the Tolerability and PK of a Single Dose of Androxal
Androxal, Placebo - Pharmacokinetics, Tolerability
Phase 1CompletedRepros Therapeutics Inc.92013-10-012014-08-11
Study of Selexipag and Its Metabolite ACT-333679 on Cardiac Repolarization in Healthy Male and Female Subjects
selexipag, placebo for selexipag, moxifloxacin - Cardiodynamics, Safety
Phase 1CompletedActelion1592012-06-012014-08-01
Single-ascending Dose Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of ACT-462206
ACT-462206 5 mg, ACT-462206 25 mg, ACT-462206 100mg - Safety, Tolerability
Phase 1CompletedIdorsia Pharmaceuticals Ltd.562011-11-012018-07-10

Showing 20 of 26. Sign in to see all of them.

Narrower conditions

Marijuana Abuse (2)  ·  Neoplasms (2)  ·  Alzheimer Disease (1)  ·  Arthritis, Rheumatoid (1)  ·  Dyskinesias (1)  ·  Parkinson Disease (1)  ·  Respiratory Aspiration (1)  ·  Stroke (1)

Broader conditions

Brain Diseases (3)  ·  Central Nervous System Diseases (3)  ·  Mental Disorders (3)  ·  Nervous System Diseases (3)  ·  Chemically-Induced Disorders (2)  ·  Neurodegenerative Diseases (2)  ·  Pathological Conditions, Signs and Symptoms (2)  ·  Substance-Related Disorders (2)  ·  Arthritis (1)  ·  Autoimmune Diseases (1)  ·  Basal Ganglia Diseases (1)  ·  Cardiovascular Diseases (1)  ·  Cerebrovascular Disorders (1)  ·  Connective Tissue Diseases (1)  ·  Dementia (1)

Interventions

ACT-462206 (1)  ·  AZD3839 (1)  ·  AZD9819 (1)  ·  AZD9977 (1)  ·  Clarithromycin (1)  ·  Didanosine (1)  ·  Dronabinol (1)  ·  Drug Interactions (1)  ·  Enclomiphene (1)  ·  Injections (1)  ·  Methoxydimethyltryptamines (1)  ·  Midazolam (1)  ·  Moxifloxacin (1)  ·  Prednisolone (1)  ·  Sodium Chloride (1)

Sponsors

AstraZeneca (7)  ·  CannaXan GmbH (2)  ·  Actelion (1)  ·  AnaMar AB (1)  ·  Astellas Pharma Europe B.V. (1)  ·  Cinclus Pharma Holding AB (1)  ·  Daiichi Sankyo (1)  ·  Idorsia Pharmaceuticals Ltd. (1)  ·  Laboratorios Sophia S.A de C.V. (1)  ·  Nanjing Immunophage Biotech Co., Ltd (1)  ·  NeuroSearch A/S (1)  ·  Neurodawn Pharmaceutical Co., Ltd. (1)  ·  RH Nanopharmaceuticals (1)  ·  Repros Therapeutics Inc. (1)  ·  SPARK Biopharma (1)

Countries

United States (9)  ·  United Kingdom (7)  ·  Germany (4)  ·  China (2)  ·  Mexico (1)  ·  Netherlands (1)  ·  Pakistan (1)  ·  South Korea (1)  ·  Sweden (1)

Top investigators

Billings W Billings, MD (1)  ·  Brendan Smyth (1)  ·  Colleen Jensen (1)  ·  David Mathews, MD (1)  ·  Dr Darren Wilbraham, MBBS DCPSA (1)  ·  Dr Paul Bjornsson (1)  ·  Izhar Hasan, MD, PhD (1)  ·  Joseph S Podolski (1)  ·  Karin Palm (1)  ·  Li Zhang, Professor (1)  ·  Matthias Hoch, PhD (1)  ·  Muhammad Raza Shah, PhD (1)  ·  Muna Albayaty, Dr. (1)  ·  Petra Baecker, MD (1)

Results publications

PMID 12750546, PMID 31601801, PMID 32087818, PMID 33148815, PMID 34487721, PMID 37185136, PMID 37832977, PMID 38258274

NIH funding

2015 (2)